GS
ABCL icon

GTS Securities’s AbCellera Biologics ABCL Stock Holding History

GTS Securities’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,400
Closed -$45.2K – 1233
2024
Q3 		$45.2K Buy
17,400
+3,400
+24% +$9.42K ﹤0.01% 3908
2024
Q2 		$41.4K Buy
14,000
+100
+0.7% +$378 ﹤0.01% 3724
2024
Q1 		$63K Sell
13,900
-9,800
-41% -$50K ﹤0.01% 3607
2023
Q4 		$135K Sell
23,700
-6,500
-22% -$30.1K ﹤0.01% 3686
2023
Q3 		$139K Buy
+30,200
New +$184K ﹤0.01% 3530

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GTS Securities's ABCL Position: Q4 2024 in Review

GTS Securities sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 21,479 shares — an estimated $55.8K sold.

GTS Securities first reported a position in ABCL in Q3 2023 and held it in 5 quarters. The position peaked at $181K in Q4 2023. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • GTS Securities reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 21,479 AbCellera Biologics shares in Q4 2024, an estimated $55.8K.
  • GTS Securities first reported a position in AbCellera Biologics in Q3 2023 and held it in 5 quarters.
  • GTS Securities's AbCellera Biologics position peaked at $181K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.